QBIO stock USD 0.0001 on PNK 13 Feb 2026: top gainer insight

QBIO stock led today’s market hours movers after trading at USD 0.0001 on the PNK exchange on 13 Feb 2026. The move shows a one-day change listed as 9,900.00%, driven by extremely low float and thin volume of 3,900 shares. We track how the price action links to Q BioMed Inc.’s pipeline, liquidity metrics, and the biotech sector backdrop to explain this top gainer appearance and what traders should watch next.

Market action driving QBIO stock momentum

QBIO stock traded at USD 0.0001 during market hours on 13 Feb 2026 on the PNK exchange in the United States. Volume was 3,900 versus an average of 6,858, highlighting thin liquidity and outsized percentage moves on small trades.

The intraday range was narrow at USD 0.0001 to USD 0.0001, while the official one-day change shows 9,900.00% because of a prior close of USD 0.000001, so headline moves reflect arithmetic from a very low base rather than large cash flows.

Company snapshot and QBIO stock fundamentals

Q BioMed Inc. (QBIO) is a US biotechnology company listed on PNK with a market cap of USD 14,509.00 and 145,090,000 shares outstanding. The company reports EPS of -0.02 and a year high of USD 0.02505, indicating prior periods of higher trading levels.

Revenue per share TTM is 0.00635 and cash per share TTM is 0.00112, showing minimal on-balance liquidity. Earnings announcement is scheduled for 29 Apr 2026, a date traders should note for potential catalyst-driven volatility.

Pipeline, partnerships and news that affect QBIO stock

Q BioMed’s portfolio includes licensed therapeutics such as Strontium Chloride SR89 and pipeline candidates Man-01, QBM-001 and Uttroside-B. The company lists a partnership with Mannin Research Inc. focused on several therapeutic areas.

These assets are the primary fundamental justification investors cite for interest in QBIO stock, but there is no recent major press release or clinical readout in public filings that would explain sustained price appreciation today. For company details see the Q BioMed website.

Technicals, trading metrics and Meyka grade

Technically, QBIO stock shows an RSI of 36.69 and an ADX of 96.75, indicating a strong trend environment on very low-priced data. On-chain momentum tools are distorted by the micro-price and thin volume, with OBV at 413,056.00 but average volume low.

Meyka AI rates QBIO with a score out of 100: 67.26 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Valuation, liquidity risk and QBIO stock risks

Primary valuation ratios are skewed by the near-zero share price. QBIO’s price-to-sales TTM is 0.05 while enterprise value is USD 4,074,517.00, producing an EV/sales of 14.33. The current ratio TTM of 0.00889 signals limited short-term liquidity on the balance sheet.

Investors face concentrated risks: micro-cap liquidity, negative EPS, operational cash needs, and sector volatility common in biotechnology. Low float can create sharp intraday moves that do not reflect underlying fundamentals.

Outlook, catalysts and QBIO stock forecast

Upcoming catalysts include the earnings report on 29 Apr 2026 and any clinical or licensing updates tied to Man-01, QBM-001, or Uttroside-B. Sector momentum in Healthcare/Biotechnology can amplify moves in small caps like Q BioMed.

Meyka AI’s forecast model projects a 12-month median target of USD 0.0010, compared with the current price of USD 0.0001, implying an upside of 900.00%. Forecasts are model-based projections and not guarantees. Traders should combine this with liquidity checks and news flow before taking positions.

Final Thoughts

QBIO stock’s top gainer status on 13 Feb 2026 reflects micro-cap dynamics more than a broad market endorsement. The share traded at USD 0.0001 on PNK with 3,900 shares changing hands, and the reported one-day percentage change of 9,900.00% stems from a prior ultra-low close. Fundamentals show EPS of -0.02, market cap USD 14,509.00, and limited cash per share, which creates clear liquidity and execution risk. Meyka AI’s forecast model projects USD 0.0010 as a 12-month median target, implying 900.00% upside from today’s price, while a higher-case target of USD 0.0050 implies larger—but speculative—upside. These projections are model-based and not guarantees. For active traders, the key paths are upcoming earnings on 29 Apr 2026 and any pipeline news. For longer-term investors, we recommend monitoring cash runway, licensing progress, and broader biotech sector trends before allocating capital. Meyka AI provides this as an AI-powered market analysis platform to help frame risk and opportunity, but this is not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.